All In Biotech

Drug Trial Radar · NCT02296190

Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm

Multi-Center, Placebo-Controlled, Dose-Ranging Phase 2 Electrophysiological Study of Intranasal Administration of MSP-2017 for the Conversion of Induced Paroxysmal Supraventricular Tachycardia (PSVT) to Sinus Rhythm

Last checked: Nov 20, 2026Latest source record: Dec 30, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 199 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

199

Actual

Start

Mar 27, 2015

Primary completion

Dec 2016

Study completion Dec 2016

Sponsor

Lead sponsor
Milestone Pharmaceuticals Inc.Academic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Medpace, Inc.
First posted
Nov 20, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to demonstrate the superiority of at least 1 dose of intranasal (IN) MSP-2017 (Etripamil) over placebo in terminating PSVT induced in an electrophysiology (EP) laboratory.

Conditions

  • Paroxysmal Supraventricular Tachycardia (PSVT)

Interventions

  • EtripamilDrug

    intranasal administration via 4 prefilled Aptar Pharma Unit-Dose Spray devices

  • PlaceboDrug

    intranasal administration via 4 prefilled Aptar Pharma Unit-Dose Spray devices

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Percentage of Subjects Successfully Converted From PSVT to Sinus Rhythm Within 15 Minutes of Study Drug AdministrationTime frame: Within 15 minutes of study drug administration

Locations

30 sites in 2 countries. Site status is shown where the registry gives one.

  • Arizona Heart Rhythm Center

    Phoenix, Arizona

  • Mayo Clinic Arizona

    Phoenix, Arizona

  • Mercy General Hospital

    Sacramento, California

  • South Denver Cardiology Associates

    Littleton, Colorado

  • Medstar Washington Hospital Center

    Washington D.C., District of Columbia

  • Memorial Hospital Jacksonville

    Jacksonville, Florida

  • Mayo Clinic Jacksonville

    Jacksonville, Florida

  • Northside Hospital

    St. Petersburg, Florida

  • University of South Florida Health South Tampa Center

    Tampa, Florida

  • Piedmont Atlanta Hospital

    Atlanta, Georgia

  • Emory University Hospital

    Atlanta, Georgia

  • Iowa Heart Center

    West Des Moines, Iowa

  • University of Kansas Medical Center

    Kansas City, Kansas

  • MedStar Health Research Institute

    Baltimore, Maryland

  • Mayo Clinic

    Rochester, Minnesota

  • Aultman Hospital Cardiology Clinical Trials

    Canton, Ohio

  • University of Cincinnati Medical Center Division of Cardiovascular Diseases

    Cincinnati, Ohio

  • ProMedica Toledo Hospital

    Toledo, Ohio

  • Great Lakes Medical Research, LLC

    Willoughby, Ohio

  • Black Hills Cardiovascular Research

    Rapid City, South Dakota

  • Texas Cardiac Arrhythmia Research Foundation

    Austin, Texas

  • Baylor St. Luke's Hospital

    Houston, Texas

  • Houston Methodist Hospital

    Houston, Texas

  • University of Virginia Medical Center

    Charlottesville, Virginia

  • Centra Stroobants Cardiovascular Center

    Lynchburg, Virginia

  • Sentara Norfolk General Hospital

    Norfolk, Virginia

  • Sunnybrook Health Sciences Center

    Toronto, Ontario, Canada

  • St. Michael's Hospital

    Toronto, Ontario, Canada

  • The Montreal Heart Institute

    Montreal, Quebec, Canada

  • CHUM Hotel Dieu

    Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.